» Articles » PMID: 28981521

Nonalcoholic Fatty Liver Disease is Associated with an Increased Risk of Heart Block in Hospitalized Patients with Type 2 Diabetes Mellitus

Overview
Journal PLoS One
Date 2017 Oct 6
PMID 28981521
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies suggested that nonalcoholic fatty liver disease (NAFLD) is associated with an increased risk of cardiac tachyarrhythmias (mainly atrial fibrillation) in patients with and without type 2 diabetes mellitus. The aim of this study was to examine whether an association also exists between NAFLD and heart block. We have retrospectively evaluated a hospital-based cohort of 751 patients with type 2 diabetes discharged from our Division of Diabetes and Endocrinology during years 2007-2014. Standard electrocardiograms were performed on all patients. Diagnosis of NAFLD was based on ultrasonography, whereas the severity of advanced hepatic fibrosis was based on the fibrosis (FIB)-4 score and other non-invasive fibrosis markers. Overall, 524 (69.8%) patients had NAFLD and 202 (26.9%) had heart block (defined as at least one block among first-degree atrio-ventricular block, second-degree block, third-degree block, left bundle branch block, right bundle branch block, left anterior hemi-block or left posterior hemi-block) on electrocardiograms. Patients with NAFLD had a remarkably higher prevalence of any persistent heart block than those without NAFLD (31.3% vs. 16.7%, p<0.001); this prevalence was particularly increased among those with higher FIB-4 score. NAFLD was associated with a threefold increased risk of prevalent heart block (adjusted-odds ratio 3.04, 95% CI 1.81-5.10), independently of age, sex, hypertension, prior ischemic heart disease, hemoglobin A1c, microvascular complication status, use of medications and other potentially confounding factors. In conclusion, this is the largest cross-sectional study to show that NAFLD and its severity are independently associated with an increased risk of prevalent heart block in hospitalized patients with type 2 diabetes.

Citing Articles

Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk.

Ionescu V, Gheorghe G, Bacalbasa N, Diaconu C Biomolecules. 2025; 15(2).

PMID: 40001466 PMC: 11852489. DOI: 10.3390/biom15020163.


Additive effect of metabolic dysfunction-associated fatty liver disease on left ventricular function and global strain in type 2 diabetes mellitus patients: a 3.0 T cardiac magnetic resonance feature tracking study.

Tang X, Shi R, Jiang L, Yan W, Han P, Qian W Cardiovasc Diabetol. 2024; 23(1):317.

PMID: 39192259 PMC: 11350936. DOI: 10.1186/s12933-024-02410-z.


Association of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With an Increased Risk of Congestive Heart Failure in Hospitalized Patients With Cirrhosis: A Propensity Score-Matched Analysis.

Ugwendum D, Mohamed M, Al-Ajlouni Y, Nso N, Njei B Cureus. 2024; 16(6):e62441.

PMID: 39011212 PMC: 11249195. DOI: 10.7759/cureus.62441.


Nonalcoholic Fatty Liver Disease as a Potential Risk Factor for Cardiovascular Disease in Patients with Type 2 Diabetes: A Prospective Cohort Study.

Dehghani Firouzabadi M, Poopak A, Sheikhy A, Dehghani Firouzabadi F, Moosaie F, Rabizadeh S Int J Endocrinol. 2024; 2024:5328965.

PMID: 38962375 PMC: 11221952. DOI: 10.1155/2024/5328965.


Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.

Simon T, Ebrahimi F, Roelstraete B, Hagstrom H, Sundstrom J, Ludvigsson J Cardiovasc Diabetol. 2023; 22(1):343.

PMID: 38093277 PMC: 10720135. DOI: 10.1186/s12933-023-02070-5.


References
1.
Targher G, Day C, Bonora E . Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363(14):1341-50. DOI: 10.1056/NEJMra0912063. View

2.
Karajamaki A, Patsi O, Savolainen M, Kesaniemi Y, Huikuri H, Ukkola O . Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS One. 2015; 10(11):e0142937. PMC: 4646339. DOI: 10.1371/journal.pone.0142937. View

3.
Mantovani A, Rigamonti A, Bonapace S, Bolzan B, Pernigo M, Morani G . Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. Diabetes Care. 2016; 39(8):1416-23. DOI: 10.2337/dc16-0091. View

4.
Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Pichiri I . Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2014; 24(6):663-9. DOI: 10.1016/j.numecd.2014.01.005. View

5.
Coumbe A, Naksuk N, Newell M, Somasundaram P, Benditt D, Adabag S . Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. Heart. 2012; 99(5):334-8. DOI: 10.1136/heartjnl-2012-302770. View